SUTRO BIOPHARMA, INC. Accretion Expense
SUTRO BIOPHARMA, INC. (STRO) reported Accretion Expense of $42.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2019-05-15
- SUTRO BIOPHARMA, INC. accretion expense for the quarter ending 2019-03-31 was $42.00K, a 10.53% increase year-over-year.
- SUTRO BIOPHARMA, INC. accretion expense for the quarter ending 2018-12-31 was $43.00K, a 60.55% decline year-over-year.
- SUTRO BIOPHARMA, INC. accretion expense for the quarter ending 2018-03-31 was $38.00K.
- SUTRO BIOPHARMA, INC. accretion expense for the quarter ending 2017-12-31 was $109.00K.
- SUTRO BIOPHARMA, INC. accretion expense for fiscal 2018 was $162.00K, a 21.80% increase from fiscal 2017.
- SUTRO BIOPHARMA, INC. accretion expense for fiscal 2017 was $133.00K.
- SUTRO BIOPHARMA, INC. accretion expense for fiscal 2016 was $0.00.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2019-03-31 | $42.00K 10-Q · filed 2019-05-15 | $85.00K derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2018-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $162.00K 10-K · filed 2019-04-01 | ||
| 2018-09-30 | $119.00K 10-Q · filed 2018-11-14 | |||
| 2018-03-31 | $38.00K 10-Q · filed 2019-05-15 | $147.00K derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $133.00K 10-K · filed 2019-04-01 | ||
| 2017-09-30 | $24.00K 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |